Latest News From Lumira Ventures

Satsuma Pharmaceuticals Raises $62 Million in Series B Preferred Stock Financing

Jennifer Schram Main Page, Portfolio News, Press Release, Satsuma Pharmaceuticals

Funding supports Phase 3 development of STS101 for the acute treatment of migraine, including pivotal Phase 3 efficacy trial with planned initiation in Q3 2019 SOUTH SAN FRANCISCO, Calif., April 24, 2019 /PRNewswire/ — Satsuma Pharmaceuticals, Inc. (“Satsuma” or “the Company”), a clinical-stage biopharmaceutical …